Search clinical trials for: PF-04518600

Total 1295 results

Pfizer

Completed

Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566

Neoplasms

United States, Netherlands, France, Japan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

Malignant Solid Neoplasm | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate... and other conditions

United States
Pfizer

Terminated

A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)

Advanced Cancer

United States, Canada, United Kingdom, Taiwan, Australia, France, Japan, Poland
University of Southern California
National Cancer Institute (NCI)

Active, not recruiting

Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer

Clear Cell Renal Cell Carcinoma | Metastatic Renal Cell Cancer | Recurrent Renal Cell Carcinoma | Stage IV Renal Cell Cancer

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Hope Rugo, MD
Johns Hopkins University; Pfizer; Gilead Sciences; Hoosier Cancer Research Network and other collaborators

Recruiting

Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer (InCITe)

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Invasive Breast Carcinoma | Unresectable Breast Carcinoma | Stage IIIC Breast Cancer | Triple-Negative Breast Carcinoma | Stage III Breast Cancer

United States
Pfizer

Completed

To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity

Healthy

United Kingdom
Pfizer

Completed

A Drug-Drug Interaction Study Between PF-06882961 and PF-06865571 in Healthy Adult Participants and Overweight Adults or Adults With Obesity Who Are Otherwise Healthy

Healthy Volunteer

United States
Pfizer

Completed

A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS

Healthy

United States
Pfizer

Completed

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia

Schizophrenia

United States
University of Florida

Completed

Potato Fiber and Gastrointestinal Function: Phase 3

Gastrointestinal Symptoms | Stool Frequency | Gastrointestinal Transit Time

United States
Pfizer

Completed

A Study to Understand the Effect of Tablet Formulation and Food on PF-06821497 in Healthy Adult Participants.

Healthy

United States
Pfizer

Completed

A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955

Healthy

United States
Pfizer

Completed

Study To Evaluate Safety, Tolerability, And Pharmacokinetics Of PF-06473871 In Normal Healthy Adults

Healthy

Belgium
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06412562 During And Following The Oral Administration Of Multiple Doses Of PF-06412562 In Healthy Adult Volunteers

Healthy

United States
Pfizer

Completed

A Study To Observe Safety And Concentrations Of PF-05297909 And Proteins In Both Blood And Cerebrospinal Fluid After A Single Dose Of PF-05297909 In Healthy Adults

Healthy

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Healthy Volunteers

Healthy

United States
Pfizer

Recruiting

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

Atopic Dermatitis

United States, Canada
Pfizer

Withdrawn

A Study To Examine The Safety And Efficacy Of PF-00610355 In Moderately Asthmatic Subjects (A7881006)

Respiratory Tract Diseases | Bronchial Diseases | Lung Diseases, Obstructive | Asthma, Bronchial
Pfizer

Completed

Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) (MIRNA)

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis With Liver Fibrosis

Hong Kong, United States, Taiwan, Puerto Rico, China, Canada, Korea, Republic of, Bulgaria, Japan, India, Poland, Slovakia
Pfizer

Completed

A Study to Understand How the Study Medicine (PF-07081532) is Processed and Eliminated in Healthy Men

Healthy Participants

Netherlands
Pfizer

Completed

A Study in Healthy Adult Male Participants to Assess Absorption, Distribution, Metabolism and Excretion (ADME) of Radiolabeled PF-06865571.

Healthy Participants

United States
Pfizer

Completed

A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes

Diabetes Mellitus, Type 1

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers

Healthy

United States
Pfizer

Recruiting

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Pfizer

Withdrawn

A Study To Look At Safety And Blood Concentrations After Multiple Doses Of PF-03382792 In Healthy Elderly Individuals

Healthy
Pfizer

Terminated

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

Healthy

United States
Pfizer

Completed

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

Healthy | Chronic Rhinosinusitis With Nasal Polyps | Atopic Dermatitis

United States
Pfizer

Completed

A Study to Evaluate Safety and Efficacy of PF-06826647 For Moderate To Severe Plaque Psoriasis

Psoriasis

Canada, United States, Japan, Poland
Pfizer

Completed

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Study To Evaluate The PDE10 Enzyme Occupancy Following A Single Dose Of PF-02545920 In Healthy Male Volunteers (PET)

Healthy

Sweden
Pfizer

Completed

A Study To Investigate How The Body Handles Multiple Doses Of PF-0243873 And To Investigate The Effect Of PF-02413873 On Sex Hormone Levels In Healthy Young Women

Endometriosis

United States, Belgium
Pfizer

Completed

STUDY OF PF-07321332 IN HEALTHY PARTICIPANTS

Healthy Participants

United States, Belgium
Pfizer

Active, not recruiting

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

Renal Cell Carcinoma | Gastric Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Squamous Cell Carcinoma of the Head and Neck | Bile Duct Cancer | Endometrial Cancer | Urothelial Cancer | Lung Squamous Cell Carcinoma | Melanoma Cancer

United States, Taiwan, Korea, Republic of, Australia, Slovakia
Invicro

Completed

D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562

Healthy Male Volunteers

United States
Pfizer

Completed

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Plaque Psoriasis | Atopic Dermatitis

United States, Canada, United Kingdom, Japan
Pfizer

Completed

A Phase 1 Study To Evaluate The Safety And Tolerability Of PF-06252616 In Healthy Subjects

Healthy

United States
Pfizer

Active, not recruiting

A Study to Understand What the Body Does to the Study Medicine Called PF-07220060 When Taken by Healthy Adults

Healthy Participants

Netherlands
Pfizer

Terminated

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR)

Prostatic Neoplasms

United States
Pfizer

Completed

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Canada
Pfizer

Completed

Study to Characterize Absorption, Distribution, Metabolism and Excretion of 14C PF-06651600 and to Evaluate the Absolute Oral Bioavailability and Fraction Absorbed of PF-06651600. (B7981011)

Healthy Volunteers

Netherlands
Pfizer

Completed

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of, Canada, United States, Australia, United Kingdom, Belgium
Pfizer

Completed

A Study To Determine The Safety, Tolerability, Skin Irritation Potential, And PK Following Topical Application Of PF-07038124 In Healthy Participants

Dermatitis Atopic

United States
Pfizer

Withdrawn

The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation

Healthy

United States
Pfizer

Terminated

A Single Dose Study Of PF-06291874 In Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

Healthy Participants

United States
Pfizer

Terminated

A Study To Evaluate The Safety And Tolerability Of PF-06342674 (RN168) In Subjects With Multiple Sclerosis (MS)

Multiple Sclerosis

United States
Pfizer

Completed

Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia

Anorexia | Breast Cancer | Fatigue | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Prostate Cancer | Cachexia | Non-small Cell Lung Cancer | Loss of Appetite

United States, Canada
Pfizer

Withdrawn

Distribution of a Single IV Dose Of [124I]-Pf 06687234 and Pf 06687234 Assessed With PET-CT Imaging In Moderate To Severe Ulcerative Colitis and Crohn's Disease

Inflammatory Bowel Disease

United States

3

Subscribe